Kolexia
Vansteene Damien Oncologie médicale
Vansteene Damien
Oncologie médicale
Institut de cancérologie de l'Ouest
Saint-Herblain, France
206 Activités
336 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Carcinome épidermoïde de la tête et du cou Tumeurs de la tête et du cou Métastase tumorale Tumeurs du sein Tumeurs colorectales Fatigue Malnutrition

Collaborateurs

Voir plus
Guigay Joel
Guigay Joel
Centre Antoine Lacassagne, Nice, France
Le Tourneau Christophe
Le Tourneau Christophe
Clcc Institut Curie, Paris, France
Raynard Bruno
Raynard Bruno
Gustave-Roussy, Villejuif, France
Saada-Bouzid Esma
Saada-Bouzid Esma
Centre Antoine Lacassagne, Nice, France

Industries

Voir plus
Merck-Serono
3 collaboration(s)
Dernière en 2022
Fresenius Kabi
3 collaboration(s)
Dernière en 2023
AstraZeneca
3 collaboration(s)
Dernière en 2020
B3TSI
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
The Lancet. Healthy longevity   05 mars 2024
COTESARC: A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.
Essai Clinique (Centre Léon-Bérard)   09 février 2024
ELAN-UNFIT: Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Essai Clinique (Merck-Serono)   07 février 2024
557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
2406P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma of the penis: Subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
923P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten): Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)
Essai Clinique (Centre Léon-Bérard)   31 août 2023
LENVAGIST: A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
Essai Clinique (Centre Léon-Bérard)   28 mars 2023